Axiom Space-tested cancer drug advances to clinical trials

mission critical

A new cancer-fighting drug will move to clinical trials after being tested on Axiom's Ax-2 and Ax-3 missions. Photo courtesy Axiom Space.

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

From Your Site Articles
Houston Methodist's Dr. Ron Moses has created NanoEar, which he calls “the world’s smallest hearing aid.” Photo via Getty Images.

Houston doctor aims to revolutionize hearing aid industry with tiny implant

small but mighty

“What is the future of hearing aids?” That’s the question that led to a potential revolution.

“The current hearing aid market and technology is old, and there are little incremental improvements, but really no significant, radical new ideas, and I like to challenge the status quo,” says Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist.

Moses is the creator of NanoEar, which he calls “the world’s smallest hearing aid.” NanoEar is an implantable device that combines the invisibility of a micro-sized tympanostomy tube with more power—and a superior hearing experience—than the best behind-the-ear hearing aid.

“You put the NanoEar inside of the eardrum in an in-office procedure that takes literally five minutes,” Moses says.

As Moses explains, because of how the human cochlea is formed, its nerves break down over time. It’s simply an inevitability that if we live long enough, we will need hearing aids.

“The question is, ‘Are we going to all be satisfied with what exists?’” he asks.

Moses says that currently, only about 20 percent of patients who need hearing aids have them. That’s because of the combination of the stigma, the expense, and the hassle and discomfort associated with the hearing aids currently available on the market. That leaves 80 percent untapped among a population of 466 million people with hearing impairment, and more to come as our population ages. In a nearly $7 billion global market, that additional 80 percent could mean big money.

Moses initially patented a version of the invention in 2000, but says that it took finding the right team to incorporate as NanoEar. That took place in 2016, when he joined forces with cofounders Michael Moore and Willem Vermaat, now the company’s president and CFO, respectively. Moore is a mechanical engineer, while Vermaat is a “financial guru;” both are repeat entrepreneurs in the biotech space.

Today, NanoEar has nine active patents. The company’s technical advisors include “the genius behind developing the brains in this device,” Chris Salthouse; NASA battery engineer Will West; Dutch physicist and audiologist Joris Dirckx; and Daniel Spitz, a third-generation master watchmaker and the original guitarist for the famed metal band Anthrax.

The NanoEar concept has done proof-of-concept testing on both cadavers at the University of Antwerp and on chinchillas, which are excellent models for human hearing, at Tulane University. As part of the TMC Innovation Institute program in 2017, the NanoEar team met with FDA advisors, who told them that they might be eligible for an expedited pathway to approval.

Thus far, NanoEar has raised about $900,000 to get its nine patents and perform its proof-of-concept experiments. The next step is to build the prototype, but completing it will take $2.75 million of seed funding.

Despite the potential for making global change, Moses has said it’s been challenging to raise funds for his innovation.

“We're hoping to find that group of people or person who may want to hear their children or grandchildren better. They may want to join with others and bring a team of investors to offset that risk, to move this forward, because we already have a world-class team ready to go,” he says.

To that end, NanoEar has partnered with Austin-based Capital Factory to help with their raise. “I have reached out to their entire network and am getting a lot of interest, a lot of interest,” says Moses. “But in the end, of course, we need the money.”

It will likely, quite literally, be a sound investment in the future of how we all hear the next generation.

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

FDA greenlights Houston surgery robotics company's unique technology

headed to clinical trials

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap.

His company is well on its way to helping to assure that, through making history of its own. EndoQuest is behind the world's first Flexible Robotic Surgical System, a technology that may one day transform surgery as we know it.

The idea to use these novel robots for surgery came from Dr. Todd Wilson, a surgeon at UTHealth Houston, who spent his medical education, residency, and fellowship at the institution.

“I had really focused in my practice on trying to do everything possible to improve outcomes for patients,” Wilson explains. “And there seemed to be a pretty good correlation that the smaller the incisions or the fewer incisions, the better patients would do.”

The stumbling block? The necessary small incisions are difficult for human surgeons to make with current technology. But UTHealth was part of the solution.

“Right there in the University of Texas was a microsurgical lab where they were focusing on trying to develop robotics, but the application was still a little bit fuzzy,” Wilson says.

Using their innovations to solve Wilson’s problem turned out to be the start of the company now known as EndoQuest Robotics.

The first indication for the system is for colon lesions. But in the future it could be used for practically any minimally invasive surgery (MIS). That means that the robots could help to perform anything from a tonsillectomy to cholecystectomy (gallbladder removal) to non-invasive colorectal procedures, should those lesions prove to be cancerous.

According to Fonseca, last year was the first on record that there were more MIS, including laparoscopic and robotic surgeries, than conventional ones in the U.S. The time is right to forge ahead with the flexible robotic surgical system. Days ago, the EndoQuest team announced that its Investigational Device Exemption (IDE) application for its pivotal colorectal clinical study was approved by the FDA.

“Our end point is a device that can be mass-manufactured and very safe for patients and has a short learning curve, so therefore, we intend to learn a lot during these trials that will inform our ultimate design,” says Fonseca.

He adds that it’s a “brilliant” group of engineers that has set EndQuest apart, including both teams in Houston and in South Korea.

“We can move twice as fast as anyone else,” jokes engineer Jiwon Choi.

Despite the extra brain power provided by the South Korea engineers, Fonseca says that EndoQuest’s beginnings are “as much of a Houston story as you could find.”

Dr. William Cohn is the chief medical officer for BiVACOR, a medical device company creating the first total artificial heart. Photo via TMC

Why this Houston medical device innovator is pumped up for the first total artificial heart

HOUSTON INNOVATORS PODCAST EPISODE 248

It's hard to understate the impact Dr. William Cohn has had on cardiovascular health as a surgeon at the Texas Heart Institute or on health care innovation as the director of the Center for Device Innovation at the Texas Medical Center. However, his role as chief medical officer of BiVACOR might be his most significant contribution to health care yet.

The company's Total Artificial Heart is unlike any cardiovascular device that's existed, Cohn explains on the Houston Innovators Podcast. While most devices are used temporarily for patients awaiting a heart transplant, BiVACOR's TAH has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

"Artificial hearts historically have had bladders that ejected and filled 144,000 times a day. They work great for temporary support, but no one is suggesting they are permanent devices," Cohn says on the show.

The difference with BiVACOR's device is it abandons the bladder approach. Cohn explains that as assist pumps evolved — something his colleague, Dr. Bud Frasier, had a huge impact on — they featured new turbine and rotor technology. Daniel Timms, BiVACOR's founder and CTO, iterated on this technology beginning when he was a postdoctoral student at Queensland University of Technology in Australia.

"BiVACOR is the first artificial heart that leverages what we learned from that whole period — it has no bladders, it has no valves. It has one moving part, and that moving part is suspended in an electromagnetic field controlled by a computer and changed thousands of times a second," Cohn says. "It will never wear out, and that's why we think it's the world's first total artificial heart."

The company is seeing momentum, celebrating its first successful human implantation last month. The device was used for eight days on a patient at Baylor St. Luke’s Medical Center before the patient received a heart transplant.

Cohn says that BiVACOR has plans to use the TAH as "bridge-to-transplant" device in several other surgeries and expects to get FDA approval for that purpose in the next three to four years before working toward clearance for total artificial heart transplants.

Cohn has worked to support medical device startups at CDI at TMC for the seven years it has existed — first under Johnson and Johnson and then under TMC when it took the program over. He describes the center and its location as the ideal place for developing the future of health care, with Houston rising up to compete with regions known for medical device success — both coasts and Minnesota.

"Being in the shadow of the largest medical center on the planet — 106,000 employees show up there every 24 hours," Cohn says, "if you want to innovate, this is the place to do it."

Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston medical device company secures $57.7M to fund journey to FDA approval, commercialization

fresh funding

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005.

Heuring says that the first prototypes were built in 2011, followed by the final design in 2018. CEO Eric Fain, a California-based MD and with more than 30 years in the medical device industry, joined the company in 2018 ahead of the final design, primed to bring Aortix to the public. He visits the company’s Houston headquarters, across the street from Central Market, on a regular basis.

The device’s pilot study of 18 patients was completed in 2022. Those encouraging results paved the way for the current study, which will include an enrollment of 134 patients. The randomized study will seek to treat patients with acute decompensated heart failure. Half will be treated with standard-of-care therapy, the other half will be catheterized with an Aortix pump. A separate arm of the study will seek to treat end-stage heart failure patients who would otherwise be deemed too sick for either a transplant or an LVAD permanent pump. Fort-five healthcare centers in the United States will participate, including Texas Heart Institute.

“One of the key characteristics is [the patients] are retaining a lot of fluid,” explains Heuring in a video interview. “And when I say a lot, I mean it could be 25 or 30 or 40 pounds of fluid or more. When we put our pump in, one of the main goals is to reduce that fluid load.”

On average, about 11 liters of fluid came off of each patient. Many of those end-stage patients had previously been considered for both a heart and kidney transplant, but after using the Aortix, their kidneys responded so well that they were able to get only the heart transplant.

“These patients really are in dire straits and come into the hospital and today the only proven therapy to help these patients is to administer high doses of intravenous diuretic and some other cardiac drugs and in about 25 percent of patients those therapies are ineffective,” says Fain.

If Aortix gains approval, these sickest of the sick, usually consigned to hospice care, will have hope.

Thanks to the Series E, led by Houston’s Fannin Partners, returning investors, including Bluebird Ventures, the Aortix is inching closer to commercialization. Besides funding the DRAIN-HR study, Procyrion will also use the funds for internal programs to improve product manufacturability. One more step towards meaning advanced heart failure may not always be a death sentence.

Last month, Atul Varadhachary, managing director of Fannin, joined the Houston Innovators Podcast and alluded to Procyrion's raise. The company was born out of Fannin and still resides in the same building as Fannin.

Aortix is a pump designed to be placed in the descending thoracic aorta of heart failure patients. Photo via Procyrion

A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Houston health tech startup secures $16M series A, prepares for first U.S. clinical trials

money moves

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients."

VenoStent's novel therapeutic medical device is a bioabsorbable wrap. Image courtesy of VenoStent

VenoStent's series A will fund the trial, expand manufacturing capabilities, and more. The company is targeting the more than 800,000 people in the U.S. with end-stage renal disease. Currently, more than half of the surgeries performed to initiate hemodialysis fail within a year. VenoStent's novel therapeutic medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

“This trial is designed to provide the highest level of clinical evidence. We’re excited to be in this position to treat the first patients in the United States with this technology, and demonstrate the safety and efficacy of our device,” continues Boire in the release.

Per the release, the company is aiming for FDA Approval and be the first-to-market device to improve hemodialysis access surgery.

“We’re extremely pleased to be partnering with VenoStent on this critical mission. This company and technology are poised for commercial success to address a critical, unmet need,” says Bob Crutchfield, operating partner at Good Growth Capital, in the release.

The TMC Venture Fund also contributed to the series A investment round, along with SNR, Baylor Angel Network / Affinity Fund, Creative Ventures, Cowtown Angels, Alumni Ventures, and other notable angel investors. Past investors in VenoStent include KidneyX, National Science Foundation, National Institute of Health, Y Combinator, Health Wildcatters, and the Texas Halo Fund.

“VenoStent’s data and traction to date is impressive and gives us a lot of confidence in their continued success. We look forward to helping them get this Breakthrough product to market and help patients that are in dire need of this innovative technology,” says Joel Whitley, partner at IAG Capital Partners, in the release.

Tim Boire is the CEO of VenoStent. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

11 can't-miss Houston business and innovation events for August

where to be

Editor's note: The tech event scene is heating up in August. From insightful talks to a young professionals summit, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Aug. 5 – Tech and Tequila Talk

Hear from guest speaker David Cohen, founder & CEO of Dallas-based Superposition, at the latest installment of Tech and Tequila Talk. The event will focus on breaking down ambiguity in data and AI projects through collaborative workshops.

This event takes place Tuesday, Aug. 5, from 5-7 p.m. at the Ion. Click here to register.

Aug. 11-16 – Black is Tech Week

Black is Tech Week will bring events for tech professionals, entrepreneurs and students to Houston through summits, career fairs, networking events and more. The event will feature speakers from Amazon, Microsoft, Google and many other companies.

This event begins Monday, Aug. 1. Find more information here.

Aug. 12 – NASA Stories at the Ion

Head to the Ion for the new morning series spotlighting the human side of space exploration. Each session will feature personal and powerful stories from astronauts and key NASA personnel. Anthony Vareha, NASA Flight Director and Flight Operations Directorate, whose primary duty is the safe operation of the International Space Station will speak this month.

This event begins Tuesday, Aug. 12, from 8:30-10 a.m. Find more information here.

Aug. 14 – Pickle Lab’s One-Year Anniversary Celebration

Enjoy an afternoon of open-play pickleball, beats by a live DJ, raffle giveaways and free swag at the first anniversary celebration of Pickle Lab in the Ion District. WonderPops will provide complimentary pops while supplies last, and Second Draught will serve each guest a free beverage.

This event takes place Thursday, Aug. 14, from 4-7 p.m. RSVP here.

Aug 19 – Navigating the Economy: Insights from Darren King

Darren King, chief investment officer of Moody Bank, will share his expert insights on the state of the economy and its impact on Houston’s future. Gain a deeper understanding of market trends, economic shifts and what they mean for businesses and individuals in the city.

This event takes place Tuesday, Aug. 19, from 11:30-1 p.m. RSVP here.

Aug. 21 – Transition on Tap

Greentown Labs’ signature networking event returns in August to foster conversations and connections within Houston's climate and energy transition ecosystem. Entrepreneurs, investors, students, philanthropists and more are invited to attend, meet colleagues, discuss solutions and engage with the growing community.

This event takes place Thursday, Aug. 21, at 5:30 p.m. at Greentown Labs. Click here to register.

Aug. 22 – Determined to Lead Women Lunch: Investing Through Market Cycles with Ellen Wilkirson

EnergyTech Nexus hosts a monthly Determined to Lead Women’s Lunch as part of its ongoing efforts to create safe spaces for women leaders in the energy transition to connect, learn and lead. The August session features Ellen Wilkirson, principal at Rev Innovations. With deep experience across traditional and transition energy sectors, Wilkirson will share how she’s approached investing through multiple market and commodity cycles and what it means to be a clean energy investor in today’s evolving landscape.

This event takes place Friday, Aug. 22, at 1 p.m. Click here to register.

Aug. 26 – Software Day at the Ion: Positioning your Startup to Capitalize on Market Trends

Software Day is a monthly series driving the support, inspiration and connections needed to help startups on their path to rapid, sustainable growth. Each month, Software Day will include office hours (by application), a keynote session and networking. This month’s panel discussion will feature Remington Tonar, co-founder of Cart.com, and Josh Teekell, founder of SmartAC.com.

This event takes place Tuesday, Aug. 26, from 3:30-7 p.m. Click here to register.

Aug. 27 – Future of Flight: Inside Venus Aerospace with Founder Sassie Duggleby

Join EO Houston for an exclusive, behind-the-scenes conversation with Sassie Duggleby, co-founder and CEO of Venus Aerospace, a Houston-based company pioneering breakthrough propulsion systems for hypersonic and space applications.

This event takes place Wednesday, Aug. 27, at 10 a.m. at Venus Aerospace. It is open to EO members and partners only. Click here to register.

Aug. 27 – The Future of American Science: A Conversation With US Rep. Brian Babin

U.S. Rep. Dr. Brian Babin and Paul Cherukuri, vice president of innovation at Rice University, will discuss how the United States remains at the forefront of space exploration, emerging technologies and scientific advancement, as well as what's next and what's at stake for the future of science policy.

This event takes place Wednesday, Aug. 27, from 3-4 p.m. at James A. Baker III Hall on Rice University's campus. Click here to register.

Aug. 28 – HYPE Summit

The third annual Houston Young Professionals and Entrepreneurs (HYPE) Summit is a day-long conference featuring panel discussions with business and thought leaders, workshop-style breakout sessions and networking opportunities. This year's event—under the theme Step Into the Spotlight—will feature speakers from First Bight Ventures, Bot Auto, Regions Bank, Lopez Negrete Communications and Umbrage.

This event takes place Thursday, Aug. 28, from 8:30 a.m.-5:30 p.m. at The Hobby Center for the Performing Arts. Click here to register.

Houston's 13 best midsize companies and more innovation news to know

Trending Topics

Editor's note: The top innovation news from the second half of the month includes new leaders at innovative Houston organizations and a ranking of the best midsize businesses from Time. Here are the five most-read InnovationMap stories from July 15-31, 2025:

13 Houston businesses appear on Time's best midsize companies of 2025

13 Houston-area businesses ranked on Time magazine's best midsize companies list. Photo via Getty Images

Houston-based engineering firm KBR tops the list of Texas businesses that appear on Time magazine and Statista’s new ranking of the country’s best midsize companies. KBR holds down the No. 30 spot, earning a score of 91.53 out of 100. Twelve other Houston-based companies landed on the list. Continue reading.

Digital Health Institute's new exec director aims to lead innovation and commercialization efforts

Pothik Chatterjee was named executive director of Rice University's and Houston Methodist's Digital Health Institute, effective May 1. Photo courtesy Rice University.

Though our existences have become deeply entangled with technology, our health has been slower to catch up. The creation late last year of the Digital Health Institute was a major step into the future for both Rice University and Houston Methodist, for whom the institute is a joint venture. The latest news for the Digital Health Institute is the appointment of Pothik Chatterjee to the role of executive director. Continue reading.

Houston hardtech accelerator names 8 scientists to 2025 cohort

Activate Houston has named eight fellows to its 2025 cohort. Photo courtesy the Ion.

National hardtech-focused organization Activate has named its 2025 cohort of scientists, which includes new members to Activate Houston. The Houston hub was introduced last year, and joins others in Boston, New York, and Berkley, California, where Activate is headquartered. Collectively, the 2025 Activate Fellowship consists of 47 scientists and engineers from nine U.S. states. Continue reading.

Rice biotech accelerator appoints 2 leading researchers to team

The Rice Biotech Launch Pad has named two bioengineering professors to its leadership team. Photo courtesy Rice University.

The Rice Biotech Launch Pad, which is focused on expediting the translation of Rice University’s health and medical technology discoveries into cures, has named Amanda Nash and Kelsey L. Swingle to its leadership team. Both are assistant professors in Rice’s Department of Bioengineering and will bring “valuable perspective” to the Houston-based accelerator. Continue reading.

Innovation Labs @ TMC set to launch for early-stage life science startups

Innovation Labs @ TMC will open next year at the TMC Innovation Factory. Photo courtesy JLABS.

The Texas Medical Center will launch its new Innovation Labs @ TMC in January 2026 to better support life science startups working within the innovation hub. The 34,000-square-foot space, located in the TMC Innovation Factory will feature labs and life science offices and will be managed by TMC. Continue reading.

Intuitive Machines lands $9.8M to complete orbital transfer vehicle

space funding

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, has secured a $9.8 million Phase Two government contract for its orbital transfer vehicle.

The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin, according to a news release from the company.

Intuitive Machine's orbital transfer vehicle (OTV) is designed to transfer payloads between Earth's orbit and the Moon and is built around the company's Nova-C lander, which has been a part of two successful lunar missions.

“Our OTV is a direct evolution of our lunar surface delivery missions—positioning us to expand into the rapidly growing market for in-space logistics,” Steve Altemus, Intuitive Machines CEO, said in the release. “We’re leveraging our flight-proven technology to operate a mission-ready service that delivers customer payloads across orbits—from Earth to the Moon and beyond.”

The company says the fast, flexible vehicle could be used for orbital servicing, logistics and communications in medium earth orbit, low lunar orbit and a variety of other destinations.

Intuitive Machines expects to begin manufacturing and flight integration as soon as 2026, once the design review is completed.

The non-NASA contract is for an undisclosed government customer, which Intuitive Machines says reinforces its "strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations."

The company has received millions from NASA for its lunar rover, lunar lander, science and technology payloads, and communications and navigation services over the years. It also recently landed up to $10 million to help develop an Earth re-entry vehicle and in-space biomanufacturing lab from Texas's Space Exploration and Research Fund.

Earlier this month, the City of Houston agreed to add three acres of commercial space for Intuitive Machines at the Houston Spaceport at Ellington Airport. Read more here.

View All Listings